Incidence and prevalence of neuroendocrine tumors of the lung: analysis of a US commercial insurance claims database

Abstract Background As reported in Surveillance, Epidemiology, and End Results (SEER) data, US incidence and prevalence of neuroendocrine tumors (NET) has increased over recent years. The study objective was to update incidence and prevalence information for lung NET using administrative claims. Methods This descriptive epidemiological study used 2009–2014 data from 2 US claims databases: MarketScan and PharMetrics. Patients (18–64 years old) had ≥1 inpatient or ≥ 2 outpatient claims with NET of bronchus or lung, identified by International Classification of Diseases, 9th Revision, Clinical Modification diagnosis codes. Prevalence was number of lung NET patients divided by number of enrollees/year. Incidence was number of patients with a first observed NET diagnosis who were disease-free for 2 years prior, divided by number of enrollees. Age and gender adjustments performed. Results The annual number of patients with lung NET identified from 2009 to 2014 ranged from 435 to 796 (MarketScan) and 419–648 (PharMetrics). In MarketScan, there was a 7.4% (95%CI 2.1–13.0; p = 0.027) annual percent change (APC) in the age-adjusted incidence for males and 6.8% (− 0.2–14.3; 0.052) for females. In PharMetrics, APC was − 2.9% (− 13.8–9.4; 0.395) for males; 14.7% (− 12.9–51.2; 0.165) for females. In MarketScan, APC in age-adjusted prevalence for males was 9.9% (4.7–15.3; 0.006); 16.2% (11.4-21.1; <.001) for females. For PharMetrics, APCs were 9.5% (2.3–17.2; 0.021) for males; 16.3% (9.6–23.5; 0.002) for females. Conclusions From 2009 to 2014 there was a statistically significant increase in age-adjusted lung NET incidence for males in MarketScan, and a statistically significant increase in age-adjusted prevalence for both genders in PharMetrics. Incidence and prevalence changes, to the extent they exist, may be due to better diagnostic methods, increased awareness of NET among clinicians and pathologists, and/or an actual increase in US disease occurrence. Differences in rates across databases are difficult to explain. These results suggest the need for awareness of the clinically effective and safe treatment options available for lung NET patients among healthcare providers